Skip to main content
SpringerLink
Log in

Are QOL measurements for patients with dementia any use?

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Walker MD, Salek MD, Bayer AJ. A review of quality of life in Alzheimer’s disease. Part 1: issues in assessing disease impact. Pharmacoeconomics 1998 Nov; 14: 499–530

    Article  PubMed  CAS  Google Scholar 

  2. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1980–1990 findings. Int J Epidemiol 1991; 20: 736–48

    Article  PubMed  CAS  Google Scholar 

  3. Salek SS, Walker MD, Bayer AJ. A review of quality of life in Alzheimer’s disease. Part 2: issues in assessing drug effects. Pharmacoeconomics 1998 Dec; 14: 613–27

    Article  PubMed  CAS  Google Scholar 

  4. Ramsay M, Winget C, Higginson I. Review: measures to determine the outcome of community services for people with dementia. Age Ageing 1995; 24: 73–83

    Article  PubMed  CAS  Google Scholar 

  5. Whitehouse PJ. Cholinesterase inhibitors in Alzheimer’s disease: are they worth the cost? CNS Drugs 1999 Mar; 11(3): 167–73

    Article  Google Scholar 

  6. Busschbach JJV, Brouwer WBF, van der Donk A, et al. An outline for a cost-effectiveness analysis of a drug for patients with Alzheimer’s disease. Pharmacoeconomics 1998 Jan; 13 (1 Pt 1): 21–34

    Article  PubMed  CAS  Google Scholar 

  7. Whitehouse PJ, Orgogozo J-M, Becker RE, et al. Quality-of-life assessment in dementia drug development: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997 Jan; 11 (Suppl. 3): 56–60

    PubMed  Google Scholar 

  8. Cummings JL. Changes in neuropsychiatric symptoms as outcome measures in clinical trials with cholinergic therapies for Alzheimer disease. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 4: S1–S9

    PubMed  Google Scholar 

  9. Wood S, Cummings JL. Measuring outcomes in Alzheimer’s disease research: assessment of the effectiveness of interventions. Dis Manage Health Outcomes 1999 Jan; 5: 1–12

    Google Scholar 

  10. Clipp EC, George LK. Dementia and cancer: a comparison of spouse caregivers. Gerontologist 1993; 33(4): 534–41

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Are QOL measurements for patients with dementia any use?. Drugs Ther. Perspect 14, 14–16 (1999). https://doi.org/10.2165/00042310-199914030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199914030-00005

Keywords

Search

Navigation